Compare SNGX & ARTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | ARTW |
|---|---|---|
| Founded | 1987 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 11.2M |
| IPO Year | 2006 | 1996 |
| Metric | SNGX | ARTW |
|---|---|---|
| Price | $0.36 | $3.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 200.3K | 29.5K |
| Earning Date | 05-08-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.03 | ★ 233.33 |
| EPS | N/A | ★ 0.04 |
| Revenue | $119,371.00 | ★ $22,975,408.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $75.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $2.05 |
| 52 Week High | $2.86 | $4.17 |
| Indicator | SNGX | ARTW |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 55.63 |
| Support Level | $0.35 | $2.53 |
| Resistance Level | $0.42 | $3.18 |
| Average True Range (ATR) | 0.01 | 0.16 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.18 | 62.96 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.